Skip to content

Comparison of an Acceleromyography- and Electromyography-based Neuromuscular Monitor With TOF-Watch ® Monitor

Comparison of an Acceleromyography- and Electromyography-based Neuromuscular Monitor With TOF-Watch ® Monitor:a Pilot Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05632107
Enrollment
100
Registered
2022-11-30
Start date
2023-03-01
Completion date
2027-12-01
Last updated
2026-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromuscular Blockade

Keywords

neuromuscular blocking agents; residual neuromuscular blockade; neuromuscular monitoring; acceleromyography; electromyography

Brief summary

A quantitative neuromuscular monitoring device is desirable to titrate the depth of neuromuscular block (NMB) during a procedure, and to prevent residual effects after removal of the endotracheal tube. Unfortunately, the most widely used monitoring technique acceleromyography (AMG) typically implies a series of cumbersome installation and calibration procedures that frequently precludes correct use of these devices in clinical practice. Electromyography (EMG) has recently attracted a lot of attention as an alternative strategy to compensate for the deficiency of AMG-based neuromuscular monitors. Nowadays, a new technology that allows for the simultaneous acquisition of EMG and AMG signals is commercially available. Although its reliability has been rapidly accepted in Physical Medicine and Rehabilitation, the use of the technique in neuromuscular monitoring has never been reported. The aim of the present study is to assess the validity of the new device for estimating the neuromuscular block by comparing with TOF Watch®-SX, which is the most widely accepted AMG-based neuromuscular monitor that has been practiced in the clinical arena for decades.

Interventions

DEVICETOF-Watch®;DELSYS® Wireless surface EMG

TOF-Watch® is the most widely accepted AMG-based neuromuscular monitor; and DELSYS® Wireless surface EMG is a new technology that allows for the simultaneous acquisition of EMG and AMG signals in a wireless manner.

Sponsors

Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Age less than 18 yr * American Society of Anesthesiologists Physical Status I to III * Elective surgery requiring muscle relaxation * Patients participated voluntarily and signed informed consent

Exclusion criteria

* Patients with known neuromuscular disorder * Stroke * Patients with a history of allergic reaction toneuromuscular blocking agents * Use of medications that might interfere with neuromuscular transmission * Any previous injury to the examined arm that might influence nerve conduction parameters * Pacemaker

Design outcomes

Primary

MeasureTime frame
Assessing the correlation between the train-of-four (TOF) obtained from the 2 devicesPerioperative data
Assessing the correlation between the posttetanic count (PTC) obtained from the 2 devicesPerioperative data

Secondary

MeasureTime frame
Screening for eligible individual signal sources from the multiplex information of the new technology for improving neuromuscular monitoringPerioperative data

Countries

China

Contacts

CONTACTHua Zheng, Dr.
hzheng@hust.edu.cn0086-27-83663173
STUDY_DIRECTORHua Zheng, Dr.

Department of Anesthesiology, Tongji Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026